Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novasep Appoints Fine Chemicals Market Director

Published: Thursday, June 06, 2013
Last Updated: Thursday, June 06, 2013
Bookmark and Share
Company strengthens its position by appointing Udo Steinhauer.

Novasep has announced that it has strengthened its position in the fine chemicals marketplace with the appointment of Udo Steinhauer as fine chemicals market director within the synthesis business unit of Novasep.

Udo Steinhauer has a strong industrial experience gained over 18 years in diverse managerial positions.

At Novasep, he will initially focus on four key business areas for Novasep: electronic, cosmetic, flavor and fragrance, and the polymer and biopolymer industry.

“The need for new organic synthesis and purification routes is now critical in the development of the specialty chemicals market,” said Udo Steinhauer.

Steinhauer continued, “As an example, the demand for new organic electronic chemicals in ultrapure quality is continuing to increase. Impurities in cosmetic active ingredients then have to be removed in order to avoid side effects. Another example is in the polymer industry. New additives are required to fulfill the demands of performance plastics and polymers obtained from new synthesis or purification routes of bio-based building blocks. I wanted to join Novasep, with its strong expertise and extended capabilities in organic synthesis and advanced purification, because it is an established player in these markets. It is able to offer a cost-effective response to these increasingly demanding manufacturing challenges.”

“Udo’s appointment is the next significant step in formalizing and developing Novasep’s position in these fine chemical markets,” said Michel Blanc, VP sales and business development of Novasep’s Synthesis Business Unit.

Blanc continued, “These industries require more and more skills in combining smart synthesis with high efficiency purification to develop innovative molecules.”

Novasep offers contract manufacturing solutions using an unparalleled array of specialized techniques that very few companies can handle at one time. This includes hazardous chemistry and large scale chromatography.

The technologies developed by Novasep often allow shorter synthetic pathways and therefore enable significant reduction of costs, time to market and environmental impact.

Novasep’s range of advanced purification techniques include membrane filtration, large scale HPLC, SMB and Varicol® continuous chromatography with integrated solvent recycling capabilities to drastically reduce operating costs.

The main reactions mastered at Novasep at industrial scale include oxidation, azides, nitration, the use of hydrazine, Grignards, alkyllithium, lithium aluminum hydride, carbon disulfide, nitroalkanes and carbonylation reactions.

By outsourcing with Novasep, clients can benefit from Novasep’s 140 years of experience in handling energetic and hazardous chemistry, thereby reducing risk and avoiding CAPEX.

The company offers a full range of integrated services including process development, scale-up and manufacturing from kilogram scale to 1,000’s of tons per year.

In addition to custom manufacturing services, Novasep also provides building blocks, intermediates and specialized reagents.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep, Triclinic Labs Partner
Partnership will enable Novasep to offer early-stage solid-state chemistry services in North America.
Thursday, September 15, 2016
Novasep Appoints Dr. François D’Hooge as Bioconjugation Unit Manager
Dr. D’Hooge will manage Novasep’s new antibody drug conjugates (ADC) production facility in Le Mans, France, currently undergoing completion.
Tuesday, September 06, 2016
Novasep, GTP Technology Join Forces
Partnership offers biotech firms full CDMO services at all development stages from gene to end product.
Tuesday, March 22, 2016
Novasep Strengthens its Advisory Board
Professors Alois Fürstner and Alois Jungbauer, renowned experts in catalysis and purification processes, will help boost innovation at Novasep
Tuesday, September 29, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep’s €4 M ADC Manufacturing Plant Extension Commissioned
The new Highly Potent API manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
Friday, May 16, 2014
Novasep Appoints CEO Michel Spagnol as Chairman
Novasep presents strategic developments.
Wednesday, March 05, 2014
Novasep Opens Indian Subsidiary
New office will meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Tuesday, December 10, 2013
Novasep’s European Custom Manufacturing Passes FDA Inspection
Two successful FDA inspections assure customers of Novasep’s strict compliance with US pharmaceutical processing standards.
Thursday, October 24, 2013
Novasep Appoints Christian Thiry as Chief Financial Officer
CFO appointment is a key milestone in Novasep’s senior management recruitment program.
Thursday, August 29, 2013
Novasep Appoints President and CEO
Novasep announces the appointment of Michel Spagnol as President and CEO of the company, effective from 25 June 2013.
Thursday, June 27, 2013
Novasep Invests to Build World's Largest Chromatography Plant for the Pharmaceutical Industry
The investment of €30 million allows Novasep to build the largest chromatography plant for the production of a large volume commercial API’s in Mourenx, France.
Wednesday, October 10, 2012
Changes to Novasep Governance
Roger-Marc Nicoud becomes non-executive chairman of the board.
Wednesday, October 03, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Developing a Vaccine for Sexually Transmitted and Insect-Borne Zika Infections
Prokarium announce the beginning of a programme to develop an oral vaccine against Zika infection.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!